Article
Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients.
The pharmacogenomics journal - 1 Jun 2013
Owen S A, Hider S L, Martin P, Bruce I N, Barton A, Thomson W
Abstract excerpt
We investigated the effect of single-nucleotide polymorphisms (SNPs) spanning 10 methotrexate (MTX) pathway genes, namely AMPD1, ATIC, DHFR, FPGS, GGH, ITPA, MTHFD1, SHMT1, SLC19A1 (RFC) and TYMS on the outcome of MTX treatment in a UK rheumatoid arthritis (RA) patient cohort. Tagging SNPs were selected and genotyping was performed in 309 patients with predefined outcomes to MTX treatment. Of the 129 SNPs tested,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
